PortfoliosLab logo
ARQT vs. QCOM
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between ARQT and QCOM is 0.29, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


Performance

ARQT vs. QCOM - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Arcutis Biotherapeutics, Inc. (ARQT) and QUALCOMM Incorporated (QCOM). The values are adjusted to include any dividend payments, if applicable.

-50.00%0.00%50.00%100.00%December2025FebruaryMarchAprilMay
-38.00%
91.05%
ARQT
QCOM

Key characteristics

Sharpe Ratio

ARQT:

0.95

QCOM:

-0.42

Sortino Ratio

ARQT:

1.78

QCOM:

-0.35

Omega Ratio

ARQT:

1.20

QCOM:

0.95

Calmar Ratio

ARQT:

0.87

QCOM:

-0.42

Martin Ratio

ARQT:

5.30

QCOM:

-0.72

Ulcer Index

ARQT:

13.20%

QCOM:

25.73%

Daily Std Dev

ARQT:

73.21%

QCOM:

43.48%

Max Drawdown

ARQT:

-95.02%

QCOM:

-86.75%

Current Drawdown

ARQT:

-63.45%

QCOM:

-35.09%

Fundamentals

Market Cap

ARQT:

$1.82B

QCOM:

$153.11B

EPS

ARQT:

-$1.16

QCOM:

$9.80

PS Ratio

ARQT:

9.35

QCOM:

4.03

PB Ratio

ARQT:

11.66

QCOM:

6.04

Total Revenue (TTM)

ARQT:

$146.97M

QCOM:

$42.29B

Gross Profit (TTM)

ARQT:

$131.10M

QCOM:

$23.55B

EBITDA (TTM)

ARQT:

-$82.41M

QCOM:

$13.28B

Returns By Period

In the year-to-date period, ARQT achieves a -2.98% return, which is significantly higher than QCOM's -5.04% return.


ARQT

YTD

-2.98%

1M

1.69%

6M

29.95%

1Y

69.15%

5Y*

-11.25%

10Y*

N/A

QCOM

YTD

-5.04%

1M

16.40%

6M

-15.19%

1Y

-18.02%

5Y*

15.00%

10Y*

10.91%

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

ARQT vs. QCOM — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

ARQT
The Risk-Adjusted Performance Rank of ARQT is 8282
Overall Rank
The Sharpe Ratio Rank of ARQT is 8383
Sharpe Ratio Rank
The Sortino Ratio Rank of ARQT is 8383
Sortino Ratio Rank
The Omega Ratio Rank of ARQT is 7676
Omega Ratio Rank
The Calmar Ratio Rank of ARQT is 8282
Calmar Ratio Rank
The Martin Ratio Rank of ARQT is 8888
Martin Ratio Rank

QCOM
The Risk-Adjusted Performance Rank of QCOM is 2929
Overall Rank
The Sharpe Ratio Rank of QCOM is 2929
Sharpe Ratio Rank
The Sortino Ratio Rank of QCOM is 2828
Sortino Ratio Rank
The Omega Ratio Rank of QCOM is 2828
Omega Ratio Rank
The Calmar Ratio Rank of QCOM is 2525
Calmar Ratio Rank
The Martin Ratio Rank of QCOM is 3737
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

ARQT vs. QCOM - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Arcutis Biotherapeutics, Inc. (ARQT) and QUALCOMM Incorporated (QCOM). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


The current ARQT Sharpe Ratio is 0.95, which is higher than the QCOM Sharpe Ratio of -0.42. The chart below compares the historical Sharpe Ratios of ARQT and QCOM, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio0.002.004.006.008.00December2025FebruaryMarchAprilMay
0.95
-0.42
ARQT
QCOM

Dividends

ARQT vs. QCOM - Dividend Comparison

ARQT has not paid dividends to shareholders, while QCOM's dividend yield for the trailing twelve months is around 2.34%.


TTM20242023202220212020201920182017201620152014
ARQT
Arcutis Biotherapeutics, Inc.
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
QCOM
QUALCOMM Incorporated
2.34%2.18%2.18%2.67%1.47%1.69%2.81%4.27%3.50%3.17%3.72%2.17%

Drawdowns

ARQT vs. QCOM - Drawdown Comparison

The maximum ARQT drawdown since its inception was -95.02%, which is greater than QCOM's maximum drawdown of -86.75%. Use the drawdown chart below to compare losses from any high point for ARQT and QCOM. For additional features, visit the drawdowns tool.


-70.00%-60.00%-50.00%-40.00%-30.00%-20.00%December2025FebruaryMarchAprilMay
-63.45%
-35.09%
ARQT
QCOM

Volatility

ARQT vs. QCOM - Volatility Comparison

The current volatility for Arcutis Biotherapeutics, Inc. (ARQT) is 19.14%, while QUALCOMM Incorporated (QCOM) has a volatility of 20.20%. This indicates that ARQT experiences smaller price fluctuations and is considered to be less risky than QCOM based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


10.00%15.00%20.00%25.00%December2025FebruaryMarchAprilMay
19.14%
20.20%
ARQT
QCOM

Financials

ARQT vs. QCOM - Financials Comparison

This section allows you to compare key financial metrics between Arcutis Biotherapeutics, Inc. and QUALCOMM Incorporated. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.002.00B4.00B6.00B8.00B10.00B12.00B20212022202320242025
71.36M
10.98B
(ARQT) Total Revenue
(QCOM) Total Revenue
Values in USD except per share items

ARQT vs. QCOM - Profitability Comparison

The chart below illustrates the profitability comparison between Arcutis Biotherapeutics, Inc. and QUALCOMM Incorporated over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

Gross Margin
Operating Margin
Net Margin
Quarterly
Annual

60.0%70.0%80.0%90.0%100.0%20212022202320242025
90.3%
55.0%
(ARQT) Gross Margin
(QCOM) Gross Margin
ARQT - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, Arcutis Biotherapeutics, Inc. reported a gross profit of 64.46M and revenue of 71.36M. Therefore, the gross margin over that period was 90.3%.

QCOM - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, QUALCOMM Incorporated reported a gross profit of 6.04B and revenue of 10.98B. Therefore, the gross margin over that period was 55.0%.

ARQT - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, Arcutis Biotherapeutics, Inc. reported an operating income of -7.63M and revenue of 71.36M, resulting in an operating margin of -10.7%.

QCOM - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, QUALCOMM Incorporated reported an operating income of 3.12B and revenue of 10.98B, resulting in an operating margin of 28.4%.

ARQT - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, Arcutis Biotherapeutics, Inc. reported a net income of -10.79M and revenue of 71.36M, resulting in a net margin of -15.1%.

QCOM - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, QUALCOMM Incorporated reported a net income of 2.81B and revenue of 10.98B, resulting in a net margin of 25.6%.